BETA

Beta Drugs Share Price

₹1,983.00 -32 (-1.59%)

21 Nov, 2024 14:02

SIP TrendupStart SIP in BETA

Start SIP

Performance

  • Low
  • ₹1,931
  • High
  • ₹2,027
  • 52 Week Low
  • ₹1,060
  • 52 Week High
  • ₹2,326
  • Open Price₹2,016
  • Previous Close₹2,015
  • Volume3,200

Investment Returns

  • Over 1 Month + 4.8%
  • Over 3 Month + 41.14%
  • Over 6 Month + 66.62%
  • Over 1 Year + 65.25%
SIP Lightning

Smart Investing Starts Here Start SIP with Beta Drugs for Steady Growth!

Invest Now

Beta Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 1,906
  • P/B Ratio
  • 12.1
  • Average True Range
  • 111.03
  • EPS
  • 37.9
  • Dividend Yield
  • 0
  • MACD Signal
  • 82.93
  • RSI
  • 55.74
  • MFI
  • 74.28

Beta Drugs Financials

Beta Drugs Technicals

EMA & SMA

Current Price
₹1,983.00
-32 (-1.59%)
pointer
  • stock-down_img
  • Bullish Moving Average 11
  • stock-up_img
  • Bearish Moving Average 5
  • 20 Day
  • ₹1,974.34
  • 50 Day
  • ₹1,832.68
  • 100 Day
  • ₹1,673.98
  • 200 Day
  • ₹1,495.47

Resistance and Support

2012.65 Pivot Speed
  • R3 2,084.25
  • R2 2,059.60
  • R1 2,037.30
  • S1 1,990.35
  • S2 1,965.70
  • S3 1,943.40

What's your outlook on Beta Drugs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Beta Drugs Ltd. specializes in manufacturing and marketing oncology pharmaceutical products, including injectable and oral formulations. The company operates advanced manufacturing facilities in India, providing high-quality cancer treatment solutions to domestic and international markets.

Beta Drugs has an operating revenue of Rs. 822.79 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 16% is great, ROE of 23% is exceptional. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 40% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 92 which is a GREAT score indicating consistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Beta Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-06 Quarterly Results
2024-10-19 To consider Fund Raising
2024-05-14 Audited Results
2023-11-07 Quarterly Results & Others To consider the Migration of the Equity shares of the Company from Emerge-SME Platform of National Stock Exchange of India Limited ( NSE Emerge ) to the Main board of NSE and BSE.
2023-05-08 Audited Results

Beta Drugs F&O

Beta Drugs Shareholding Pattern

66.73%
1.15%
21.71%
10.41%

About Beta Drugs

  • NSE Symbol
  • BETA
  • BSE Symbol
  • 531481
  • Chairperson & Managing Director
  • Mr. Rahul Batra
  • ISIN
  • INE351Y01019

Similar Stocks to Beta Drugs

Beta Drugs FAQs

Beta Drugs share price is ₹1,983 As on 21 November, 2024 | 13:48

The Market Cap of Beta Drugs is ₹1906.4 Cr As on 21 November, 2024 | 13:48

The P/E ratio of Beta Drugs is As on 21 November, 2024 | 13:48

The PB ratio of Beta Drugs is 12.1 As on 21 November, 2024 | 13:48

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23